CN111936147A - γ聚谷氨酸化抗叶酸剂及其用途 - Google Patents
γ聚谷氨酸化抗叶酸剂及其用途 Download PDFInfo
- Publication number
- CN111936147A CN111936147A CN201980024669.5A CN201980024669A CN111936147A CN 111936147 A CN111936147 A CN 111936147A CN 201980024669 A CN201980024669 A CN 201980024669A CN 111936147 A CN111936147 A CN 111936147A
- Authority
- CN
- China
- Prior art keywords
- composition
- gamma
- cancer
- antifolate
- pantol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862627732P | 2018-02-07 | 2018-02-07 | |
US201862627733P | 2018-02-07 | 2018-02-07 | |
US62/627,732 | 2018-02-07 | ||
US62/627,733 | 2018-02-07 | ||
US201862630620P | 2018-02-14 | 2018-02-14 | |
US201862630625P | 2018-02-14 | 2018-02-14 | |
US201862630824P | 2018-02-14 | 2018-02-14 | |
US201862630613P | 2018-02-14 | 2018-02-14 | |
US201862630751P | 2018-02-14 | 2018-02-14 | |
US201862630652P | 2018-02-14 | 2018-02-14 | |
US62/630,824 | 2018-02-14 | ||
US62/630,751 | 2018-02-14 | ||
US62/630,652 | 2018-02-14 | ||
US62/630,620 | 2018-02-14 | ||
US62/630,625 | 2018-02-14 | ||
US62/630,613 | 2018-02-14 | ||
US201862636289P | 2018-02-28 | 2018-02-28 | |
US62/636,289 | 2018-02-28 | ||
US201862662372P | 2018-04-25 | 2018-04-25 | |
US62/662,372 | 2018-04-25 | ||
US201862702774P | 2018-07-24 | 2018-07-24 | |
US201862702779P | 2018-07-24 | 2018-07-24 | |
US62/702,774 | 2018-07-24 | ||
US62/702,779 | 2018-07-24 | ||
US201862764945P | 2018-08-17 | 2018-08-17 | |
US201862764951P | 2018-08-17 | 2018-08-17 | |
US62/764,945 | 2018-08-17 | ||
US62/764,951 | 2018-08-17 | ||
PCT/US2019/017004 WO2019157148A1 (en) | 2018-02-07 | 2019-02-07 | Gamma polyglutamated antifolates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111936147A true CN111936147A (zh) | 2020-11-13 |
Family
ID=67548055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980024669.5A Pending CN111936147A (zh) | 2018-02-07 | 2019-02-07 | γ聚谷氨酸化抗叶酸剂及其用途 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3749321A4 (ja) |
JP (1) | JP7490240B2 (ja) |
CN (1) | CN111936147A (ja) |
CA (1) | CA3090505A1 (ja) |
WO (1) | WO2019157148A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114555127A (zh) * | 2019-08-06 | 2022-05-27 | L.E.A.F.控股集团公司 | 制备聚谷氨酸化抗叶酸剂的方法以及它们的组合物的用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
CN109689104A (zh) | 2016-08-12 | 2019-04-26 | L.E.A.F.控股集团公司 | α和γ-D聚谷氨酸化抗叶酸剂及其用途 |
WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
WO2019157138A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
EP3752158A4 (en) * | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
WO2019160735A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
EP3752155A4 (en) * | 2018-02-14 | 2022-03-16 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMIC METHOTREXATE AND ITS USES |
US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050209239A1 (en) * | 2004-03-12 | 2005-09-22 | Barton Kamen | Compositions and methods employing aminopterin |
US20060160751A1 (en) * | 2005-01-07 | 2006-07-20 | Mcguire John J | 5-Amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
US20080214585A1 (en) * | 2007-01-19 | 2008-09-04 | Chelsea Therapeutics, Inc. | New classical antifolates |
US20080234298A1 (en) * | 2006-12-29 | 2008-09-25 | Tracon Pharmaceuticals, Inc. | Antifolate agent combinations in the treatment of cancer |
US20080288177A1 (en) * | 2006-08-30 | 2008-11-20 | Hendrik Jan Guchelaar | Pharacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis |
CN106794164A (zh) * | 2014-08-14 | 2017-05-31 | L.E.A.F.控股集团公司 | 脂质体包封的亲和性药物 |
US20180236098A1 (en) * | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
AU2001231154A1 (en) * | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
JP2008512490A (ja) * | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス,インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
CN102480945A (zh) * | 2009-06-03 | 2012-05-30 | 艾克斯特克有限责任公司 | 皮肤处理组合物 |
US9770414B2 (en) * | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
CN103040748B (zh) * | 2012-12-18 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种培美曲塞二钠脂质体注射剂 |
CN109689104A (zh) * | 2016-08-12 | 2019-04-26 | L.E.A.F.控股集团公司 | α和γ-D聚谷氨酸化抗叶酸剂及其用途 |
WO2018031980A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
EP3706801A4 (en) * | 2017-11-08 | 2022-04-06 | L.E.A.F Holdings Group LLC | PLATINUM COMPLEXES AND THEIR USES |
CA3090500A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
WO2019157123A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
WO2019157138A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
WO2019157129A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
WO2019157125A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated methotrexate and uses thereof |
CA3090391A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
CA3090381A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
CA3090483A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
WO2019157133A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
WO2019157120A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
WO2019160735A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
EP3752155A4 (en) * | 2018-02-14 | 2022-03-16 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMIC METHOTREXATE AND ITS USES |
US11771700B2 (en) * | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
WO2019160736A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
EP3752158A4 (en) * | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
-
2019
- 2019-02-07 CN CN201980024669.5A patent/CN111936147A/zh active Pending
- 2019-02-07 EP EP19752055.4A patent/EP3749321A4/en active Pending
- 2019-02-07 WO PCT/US2019/017004 patent/WO2019157148A1/en unknown
- 2019-02-07 JP JP2020542733A patent/JP7490240B2/ja active Active
- 2019-02-07 CA CA3090505A patent/CA3090505A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050209239A1 (en) * | 2004-03-12 | 2005-09-22 | Barton Kamen | Compositions and methods employing aminopterin |
US20060160751A1 (en) * | 2005-01-07 | 2006-07-20 | Mcguire John J | 5-Amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
US20080288177A1 (en) * | 2006-08-30 | 2008-11-20 | Hendrik Jan Guchelaar | Pharacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis |
US20080234298A1 (en) * | 2006-12-29 | 2008-09-25 | Tracon Pharmaceuticals, Inc. | Antifolate agent combinations in the treatment of cancer |
US20080214585A1 (en) * | 2007-01-19 | 2008-09-04 | Chelsea Therapeutics, Inc. | New classical antifolates |
CN106794164A (zh) * | 2014-08-14 | 2017-05-31 | L.E.A.F.控股集团公司 | 脂质体包封的亲和性药物 |
US20180236098A1 (en) * | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
Non-Patent Citations (2)
Title |
---|
D S DUCH,等: "Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase" * |
曹胜利,等: "抗叶酸剂类抗肿瘤药物的研究进展" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114555127A (zh) * | 2019-08-06 | 2022-05-27 | L.E.A.F.控股集团公司 | 制备聚谷氨酸化抗叶酸剂的方法以及它们的组合物的用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2019157148A1 (en) | 2019-08-15 |
JP2021513533A (ja) | 2021-05-27 |
JP7490240B2 (ja) | 2024-05-27 |
EP3749321A4 (en) | 2022-03-09 |
EP3749321A1 (en) | 2020-12-16 |
CA3090505A1 (en) | 2019-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240173321A1 (en) | Alpha polyglutamated pemetrexed and uses thereof | |
JP7487107B2 (ja) | アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用 | |
JP7490239B2 (ja) | ガンマポリグルタミン酸化ペメトレキセドおよびその使用 | |
JP7490240B2 (ja) | ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用 | |
JP7442822B2 (ja) | γポリグルタミン酸化テトラヒドロ葉酸およびその使用 | |
CN111954529A (zh) | α聚谷氨酸化氨甲蝶呤及其用途 | |
US20210154196A1 (en) | Gamma polyglutamated methotrexate and uses thereof | |
US20210052592A1 (en) | Alpha polyglutamated aminopterin and uses thereof | |
US11771700B2 (en) | Gamma polyglutamated lometrexol and uses thereof | |
US20210346381A1 (en) | Alpha polyglutamated tetrahydrofolates and uses thereof | |
US20210213019A1 (en) | Gamma polyglutamated aminopterin and uses thereof | |
US20210023006A1 (en) | Gamma polyglutamated raltitrexed and uses thereof | |
US20210338675A1 (en) | Alpha polyglutamated lometrexol and uses thereof | |
US20200360389A1 (en) | Gamma polyglutamated antifolates and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |